1407831-31-5

Basic information

• Product Name: 5-((4R)-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1-methylpyridin-2(1H)-one
• Synonyms: 5-((4R)-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1-methylpyridin-2(1H)-one
• CAS NO: 1407831-31-5
• Molecular Weight: 431.925
• Mol File: 1407831-31-5.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 5-((4R)-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1-methylpyridin-2(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((4R)-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1-methylpyridin-2(1H)-one(1407831-31-5)
• EPA Substance Registry System: 5-((4R)-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-8-yl)-1-methylpyridin-2(1H)-one(1407831-31-5)

Safety Data

• Hazardous Substances Data: 1407831-31-5(Hazardous Substances Data)

Upstream product

• 1407832-40-9 8-bromo-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4Hbenzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 
• 1407833-56-0 7-bromo-3-methyl-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one 
• 1407833-52-6 methyl 3-(2-amino-5-bromophenylamino)-2-methylpropanoate 
• 1407833-48-0 methyl 3-(5-bromo-2-nitrophenylamino)-2-methylpropanoate 
• 1002309-52-5 1-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyridin-2-one 
• 1407830-61-8 (R)-8-bromo-6-(4-chlorophenyl)-1,4-dimethyl-5,6-dihydro-4Hbenzo[b][1,2,4]triazolo[4,3-d][1,4]diazepine 
• 1407833-64-0 5,6-dihydro-1,4-dimethyl-8-bromo-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine 
• 1407833-60-6 7-bromo-3-methyl-4,5-dihydro-1H-benzo[b] [1,4] diazepine-2(3H)-thione 

Relevant articles and documents

Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET Bromodomains

Inhibition of the bromodomains of the BET family, of which BRD4 is a member, has been shown to decrease myc and interleukin (IL) 6 in vivo, markers that are of therapeutic relevance to cancer and inflammatory disease, respectively. Herein we report substituted benzo[b]isoxazolo[4,5-d]azepines and benzotriazolo[4,3-d][1,4]diazepines as fragment-derived novel inhibitors of the bromodomain of BRD4. Compounds from these series were potent and selective in cells, and subsequent optimization of microsomal stability yielded representatives that demonstrated dose- and time-dependent reduction of plasma IL-6 in mice.